Premium
MGMT methylation: A marker of response to temozolomide in low‐grade gliomas
Author(s) -
Everhard Sibille,
Kaloshi Gentian,
Crinière Emmanuelle,
BenouaichAmiel Alexandra,
Lejeune Julie,
Marie Yannick,
Sanson Marc,
Kujas Michèle,
Mokhtari Karima,
HoangXuan Khê,
Delattre JeanYves,
Thillet Joëlle
Publication year - 2006
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.21044
Subject(s) - temozolomide , methylation , methyltransferase , oncology , glioma , chemotherapy , medicine , o 6 methylguanine dna methyltransferase , glioblastoma , cancer research , biology , gene , genetics
The methylation status of the O6‐methylguanine‐methyltransferase promoter (MGMTP) was evaluated in 68 low‐grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression‐free survival as compared with unmethylated MGMTP tumors ( p < 0.0001). Assessment of MGMTP status could help identifying low‐grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies. Ann Neurol 2006;60:740–743